- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| XILIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| Mo | Xilio Names Yariv Houvras Chief Medical Officer | 1 | RTTNews | ||
| Mo | Xilio Therapeutics appoints Yariv Houvras as chief medical officer | 3 | Investing.com | ||
| Mo | Xilio Therapeutics, Inc.: Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer | 313 | GlobeNewswire (Europe) | WALTHAM, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people... ► Artikel lesen | |
| 02.09. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 12.08. | Xilio Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 12.08. | Xilio Therapeutics GAAP EPS of -$0.33, revenue of $18.7M | 2 | Seeking Alpha | ||
| 12.08. | Xilio Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 12.08. | Xilio Therapeutics, Inc.: Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates | 386 | GlobeNewswire (Europe) | Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell... ► Artikel lesen | |
| 12.08. | Xilio Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.07. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 29.06. | Xilio Therapeutics beruft Ben Harshbarger zum neuen Chief Legal Officer | 3 | Investing.com Deutsch | ||
| 29.06. | Xilio Therapeutics appoints Ben Harshbarger as chief legal officer | 4 | Investing.com | ||
| 29.06. | Xilio Therapeutics, Inc.: Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer | 735 | GlobeNewswire (Europe) | WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people... ► Artikel lesen | |
| 12.06. | Xilio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.05. | Xilio Therapeutics reports Q1 results | 1 | Seeking Alpha | ||
| 12.05. | Xilio Therapeutics, Inc.: Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates | 621 | GlobeNewswire (Europe) | On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Presented new preclinical data... ► Artikel lesen | |
| 12.05. | Xilio Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 12.05. | Xilio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.05. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,537 | -0,04 % | Valneva mit BRANDMELDUNG: Diese kritische Marke lässt Anleger zittern - Jetzt handeln, noch vor dem Wochenende! | ||
| PALATIN TECHNOLOGIES | 9,330 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| OCUGEN | 0,902 | -0,99 % | H.C. Wainwright raises Ocugen stock price target on Bahamas approval | ||
| VIVORYON THERAPEUTICS | 1,095 | -0,90 % | Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting | Vivoryon Therapeutics N.V. Reports Outcomeof 2026 Annual General Meeting
Halle (Saale) / Munich, Germany, September 29, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,520 | -0,13 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,200 | -2,31 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,500 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 6,200 | 0,00 % | RBC Capital bestätigt Rating für Ocular Therapeutix und sieht Potenzial in AMD-Therapie | ||
| VERASTEM | 6,924 | +1,17 % | Verastem presents new data on ovarian cancer drug combination | ||
| OXFORD NANOPORE TECHNOLOGIES | 2,626 | +0,15 % | IP Group sells down stake in Oxford Nanopore | ||
| VOYAGER THERAPEUTICS | 2,230 | +3,05 % | Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 | - Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 2,240 | -1,32 % | Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns? | ||
| PALISADE BIO | 1,450 | 0,00 % | Palisade Bio, Inc.: Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026 | ||
| TVARDI THERAPEUTICS | 1,120 | +9,80 % | Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update | Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations... ► Artikel lesen | |
| XBIOTECH | 1,906 | -0,21 % | XBiotech Inc.: XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis | IND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path for U.S. Patient Enrollment
AUSTIN, Texas, June 15, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:... ► Artikel lesen |
Das Unternehmen XILIO THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 9,010 Euro und damit +0,56 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XILIO THERAPEUTICS INC finden Sie auf Wallstreet Online.